Skip to main content
. Author manuscript; available in PMC: 2015 Jan 1.
Published in final edited form as: J Assoc Nurses AIDS Care. 2013 Sep 24;25(1):23–31. doi: 10.1016/j.jana.2013.07.004

Table 3.

Subject Adherence Rates

N Mean Adherence Standard Deviation Range
Overall Adherence Baseline 57 93.65 12.02 40–100
Overall Adherence 12-weeks 53 93.59 12.17 40–100
Overall Adherence 24-weeks 48 95.85 6.92 68.5–100
Psychotropic Baseline 24 91.42 14.60 40–100
Psychotropic 12-weeks 22 92.73 15.18 50–100
Psychotropic 24-weeks 20 91.50 16.31 50–100
ARV Baseline 26 95.91 10.16 50–100
ARV 12-weeks 24 92.28 15.58 40–100
ARV 24-weeks 25 96.61 6.43 80–100
Other Baseline 45 94.25 11.55 40–100
Other 12-weeks 40 96.35 8.47 60–100
Other 24-weeks 35 96.78 8.50 65–100
PEG-INF Adherence 12-weeks 47 97.87 7.05 75–100
PEG-INF Adherence 24-weeks 31 98.39 8.98 50–100
RBV Adherence 12-weeks 47 96.70 7.42 70–100
RBV Adherence 24-weeks 31 97.26 7.73 60–100

Note. ARV = antiretroviral; PEG-INF = pegylated interferon; RBV = ribavirin.

HHS Vulnerability Disclosure